200
Participants
Start Date
June 21, 2025
Primary Completion Date
November 26, 2027
Study Completion Date
February 8, 2028
Cohort A: vilobelimab
Administered as an IV formulation of 800 mg per dose and up to 6 doses (planned for Days 1, 2, 4, 8, 15, and 22, if participant is in hospital setting and deemed appropriate by the investigator)
Cohort A: placebo
Administered as an IV formulation of placebo of up to 6 doses (planned for Days 1, 2, 4, 8, 15, and 22, if participant is in hospital setting and deemed appropriate by the investigator)
RECRUITING
Montefiore Hospital - Moses Campus, The Bronx
RECRUITING
Long Beach Memorial Medical Center, Long Beach
RECRUITING
University of California Irvine Medical Center, Orange
RECRUITING
MedStar Washington Hospital Center, Washington D.C.
RECRUITING
Nova Clinical Research, Bradenton
RECRUITING
St. Luke's Boise Medical Center, Boise
RECRUITING
OSF Saint Francis Medical Center-, Peoria
RECRUITING
Lahey Hospital and Medical Center, Burlington
RECRUITING
Mayo Clinic, Rochester
WITHDRAWN
Renown Institute for Heart & Vascular Health, Reno
RECRUITING
Robert Wood Johnson Medical School, New Brunswick
RECRUITING
University of North Carolina at Chapel Hill, Chapel Hill
RECRUITING
Durham VA Medical Center, Durham
RECRUITING
Mercy Health - St. Vincent Medical Center, Toledo
RECRUITING
The University of Oklahoma Health Sciences Center, Oklahoma City
RECRUITING
Oregon Health and Science University, Portland
Lead Sponsor
Collaborators (3)
Biomedical Advanced Research and Development Authority
FED
InflaRx GmbH
INDUSTRY
Edesa Biotech Inc.
INDUSTRY
Genentech, Inc.
INDUSTRY
PPD Development, LP
INDUSTRY